EPOPROSTENOL
Generic: EPOPROSTENOL
Mylan Institutional LLCManufacturer
INTRAVENOUSRoute
EPOPROSTENOLActive Substance
2024-06-12Original Approval
EPOPROSTENOL is FDA application ANDA213913, sponsored by MYLAN. Any recalls listed below come from FDA drug enforcement reports, and reaction counts are the number of FAERS adverse event reports that mention the drug and that reaction; a report does not prove the drug caused it.
Top Reported Reactions
1
DRUG INEFFECTIVE
264 reports
2
DYSPNOEA
201 reports
3
HEADACHE
185 reports
4
OFF LABEL USE
175 reports
5
DIARRHOEA
142 reports
6
CONDITION AGGRAVATED
137 reports
7
NAUSEA
134 reports
8
RIGHT VENTRICULAR FAILURE
119 reports
9
PAIN IN JAW
103 reports
10
PULMONARY ARTERIAL HYPERTENSION
100 reports